InMed Pharmaceuticals Inc.
INM
$1.34
$0.021.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.80M | 4.94M | 4.92M | 4.83M | 4.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.80M | 4.94M | 4.92M | 4.83M | 4.96M |
| Cost of Revenue | 3.18M | 3.24M | 3.33M | 3.12M | 3.39M |
| Gross Profit | 1.62M | 1.71M | 1.60M | 1.71M | 1.57M |
| SG&A Expenses | 6.67M | 6.63M | 6.14M | 6.18M | 5.99M |
| Depreciation & Amortization | 211.50K | 212.90K | 214.90K | 217.40K | 219.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.73M | 12.86M | 13.01M | 12.60M | 12.22M |
| Operating Income | -7.93M | -7.92M | -8.08M | -7.77M | -7.26M |
| Income Before Tax | -8.21M | -8.16M | -8.30M | -7.91M | -6.81M |
| Income Tax Expenses | -- | -- | 7.10K | 7.10K | 7.10K |
| Earnings from Continuing Operations | -8.21 | -8.16 | -8.31 | -7.91 | -6.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.21M | -8.16M | -8.31M | -7.91M | -6.82M |
| EBIT | -7.93M | -7.92M | -8.08M | -7.77M | -7.26M |
| EBITDA | -7.72M | -7.71M | -7.87M | -7.55M | -7.04M |
| EPS Basic | -7.21 | -9.48 | -12.32 | -13.97 | -14.04 |
| Normalized Basic EPS | -4.51 | -5.93 | -7.69 | -8.72 | -8.76 |
| EPS Diluted | -7.21 | -9.48 | -12.32 | -13.97 | -14.04 |
| Normalized Diluted EPS | -4.51 | -5.93 | -7.69 | -8.72 | -8.76 |
| Average Basic Shares Outstanding | 7.25M | 3.91M | 2.90M | 2.29M | 1.98M |
| Average Diluted Shares Outstanding | 7.25M | 3.91M | 2.90M | 2.29M | 1.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |